• Explore /
  • Poster
  • / Safety and survival outcomes in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with lutetium-177–prostate-specific membrane antigen (<sup>177</sup>Lu-PSMA) after radium-223 (<sup>223</sup>Ra): Interim analysis of the RALU study.

Safety and survival outcomes in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with lutetium-177–prostate-specific membrane antigen (177Lu-PSMA) after radium-223 (223Ra): Interim analysis of the RALU study.

Abstract Video & Slides Poster

Authors

Kambiz Rahbar

Kambiz Rahbar

Department of Nuclear Medicine, University Hospital Münster, Münster, Germany

Kambiz Rahbar , Markus Essler , Matthias Eiber , Christian la Fougère , Vikas Prasad , Wolfgang P. Fendler , Philipp Rassek , Ergela Hasa , Helmut Dittmann , Ralph A. Bundschuh , Kim M. Pabst , Milena Kurtinecz , Per Sandstrom , Frank Verholen , A. Oliver Sartor

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Genitourinary Cancer—Prostate, Testicular, and Penile

Track

Genitourinary Cancer—Prostate, Testicular, and Penile

Sub Track

Prostate Cancer– Advanced/Castrate-Resistant

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr 5040)

DOI

10.1200/JCO.2022.40.16_suppl.5040

Abstract #

5040

Poster Bd #

224

Abstract Disclosures

Similar Posters

First Author: Johann S. De Bono

First Author: Daniel Peter Petrylak

First Author: Esmail M. Al-Ezzi

First Author: Nicholas D. James